Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
Novel approaches to improve TB treatment outcomes (to reduce morbidity, mortality, and the
duration of TB treatment) and to treat XDR-TB cases are urgently required. Host-Directed
therapies (especially repurposed drugs such as Non-Steroid AntiInflammatory Drugs NSAIDS)
could be useful in this context, and therefore the appropriateness and potential effect of
this approach needs to be evaluated in humans. Investigators do propose a prospective,
randomized, pilot study to estimate the potential efficacy and safety of using adjunctive
ibuprofen for the treatment of XDR tuberculosis.
Phase:
Phase 2
Details
Lead Sponsor:
Fundació Institut Germans Trias i Pujol
Collaborators:
National Center for Tuberculosis and Lung Disease, Tbilisi, Georgia National Center for Tuberculosis and Lung Diseases of Georgia (NCTLD)